Dados do Trabalho

Título

FATIGUE IN PATIENTS WITH SPINAL MUSCULAR ATROPHY TYPES 2 AND 3

Introdução

Fatigue is a frequent disabling primary symptom in Spinal Muscular Atrophy (SMA) patients. It results in low levels of physical activity, significantly impairing patients' quality of life.

Objetivo

To evaluate perceived and physiological fatigue in individuals with SMA type 2 and 3, and to establish its relationship with other important aspects, such as muscle strength, motor and respiratory function.

Método

We evaluated fatigue in children and adults with a confirmed genetic diagnosis for SMA, in a cross-sectional observational study, using the Fatigue Severity Scale (FSS, Portuguese version) and Multidimensional Fatigue Scale (PedsQL MFS, Portuguese version) to assessment of perceived fatigue and Repeated nine hole peg test (r9HPT) and Endurance Shuttle Walk Test (ESWT) to assess physiological fatigue. Factors associated with fatigue, including muscle strength, motor function and vital capacity (VC) were also evaluated.

Resultados e Conclusões

Results: In total, 28 participants with SMA types 2 and 3 were included, with a mean age of 20.6 ± 11.8 years. Participants' reports of perceived fatigue through the PedsQL MFS were similar to those of caregivers. Perceived fatigue was similar for SMA type 2 and 3 participants (PedsQL MFS self-report: 75.9; 70.5). Perceived fatigue was common in adult participants with 58.4% reporting abnormal or several fatigue (FSS > 4). Perceived fatigue was not associated with motor function, respiratory function and physiological fatigue. All correlations showed alpha levels of p > 0.05. In the evaluation of physiological fatigue through the r9HPT, it was observed that SMA type 2 participants showed significantly worse performance than participants with type 3. The results of the r9HPT were shown to be correlated with the VC and muscle strength of elbow flexors, with a value of p < 0.05. In ambulatory patients who performed the ESWT, none were able to complete the maximum time of 1200 seconds. The median time the test was interrupted was 186.9 seconds, which represents 16% of the maximum time.
Conclusion: Fatigue is a frequent and relevant complaint in SMA patients. The relationship between perceived and physiological fatigue is complex and requires a multifactorial approach that encompasses the various mechanisms involved in fatigue in SMA.

Palavras Chave

Spinal muscular atrophy. Fatigue. Perceived fatigue. Physiological fatigue. Fatigability.

Declaração de conflito de interesses de TODOS os autores

Declaro que nenhum dos autores apresenta conflito de interesses.

Referências (se houver)

Binz C, Schreiber-Katz O, Kumpe M, Ranxha G, Siegler H, Wieselmann G, et al. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment. Journal of Neurology. 2021;268(3):950–62.
Noto Y, Misawa S, Mori M, Kawaguchi N, Kanai K, Shibuya K, et al. Prominent fatigue in spinal muscular atrophy and spinal and bulbar muscular atrophy: Evidence of activity-dependent conduction block. Clinical Neurophysiology. 2013;124(9):1893–8.
Young DS, Montes J, Kramer SS, Podwika B, Rao AK, De Vivo DC. Perceived Fatigue in Spinal Muscular Atrophy: A Pilot Study. Journal of Neuromuscular Diseases. 2019;6(1):109
Kluger BM, Krupp LB, Enoka RM. Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy. Neurology. 2013;80(4):409–16.
Montes J, Dunaway S, Garber CE, Chiriboga CA, De Vivo DC, Rao AK. Leg muscle function and fatigue during walking in spinal muscular atrophy type 3. Muscle & Nerve. 2014;50(1):34–9.
Werlauff U, Højberg A, Firla-Holme R, Steffensen BF, Vissing J. Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation. 2014;23(5):1479–88.
Krupp LB. The Fatigue Severity Scale. Archives of Neurology. 1989;46(10):1121.
Montes J, McDermott MP, Martens WB, Dunaway S, Glanzman AM, Riley S, et al. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010;74(10):833–8.
Bartels B, Habets LE, Stam M, Wadman RI, Wijngaarde CA, Schoenmakers MAGC, et al. Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. BMC Neurology. 2019;19(1).
de Groot IJM, Voet NBM, van Middendorp H, Knoop HJA, Rahbek J, van Engelen BGM. 184th ENMC International Workshop: pain and fatigue in neuromuscular disorders: 20-22 May 2011, Naarden, The Netherlands. Neuromuscular disorders: NMD. 2013;23(12):1028–32.
Toledo FO, Junior WM, Speciali JG, Sobreira CFDR. PND66 Cross-Cultural Adaptation and Validation of the Brazilian Version of the Fatigue Severity Scale (FSS). Value in Health. 2011;14(7):329–30.
Varni JW, Limbers CA, Bryant WP, Wilson DP. The PedsQLTM Multidimensional Fatigue Scale in pediatric obesity: Feasibility, reliability and validity. International Journal of Pediatric Obesity. 2010(1):34–42.
Stam M, Wadman RI, Bartels B, Leeuw M, Westeneng H-J, Wijngaarde CA, et al. A continuous repetitive task to detect fatigability in spinal muscular atrophy. Orphanet Journal of Rare Diseases. 2018;13(1).
Bartels B, de Groot JF, Habets LE, Wijngaarde CA, Vink W, Stam M, et al. Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. Orphanet Journal of Rare Diseases. 2020;15(1).
Bartels B, Groot JF de, Habets LE, Wadman RI, Asselman F-L, Nieuwenhuis EES, et al. Correlates of Fatigability in Patients With Spinal Muscular Atrophy. Neurology. 2021;96(6):845–52.
O’Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscular Disorders. 2007;17(9-10):693–7.
Glanzman AM, O’Hagen JM, McDermott MP, Martens WB, Flickinger J, Riley S, et al. Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and III. Journal of Child Neurology. 2011;26(12):1499– 507.